HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. It has established a "1+2+3+4=1" service system and can supply raw materials of silymarin extract from multiple well-known original manufacturers. As a technology R&D-oriented foreign trade enterprise, HiSiaddi has repeatedly resolved customized demand issues for silymarin extract products through technological transformation cooperation with manufacturers and precise grasp of market demands. Below is a case of HiSiaddi addressing customized requirements for silymarin extract.
If you require further customized services, please contact HiSiaddi customer service.
The purchaser is Hepapharma GmbH based in Hamburg, Germany, a mid-to-high-end pharmaceutical enterprise specializing in raw materials for liver-protecting prescription drugs and premium liver care dietary supplements. Its products are listed in Germany’s OTC auxiliary medication catalogue and sold nationwide at German federal chain pharmacies, liver disease specialist clinics, and high-end wellness centers in Switzerland. Raw material access complies with EU EC396 standard covering 226 pesticide residue items, German LFGB, USP Pharmacopoeia, REACH Regulation, as well as EU veterinary and food raw material control standards.
The enterprise has long sourced European-origin silymarin extract from Hungary. Plagued by successive extreme weather events in European producing regions triggering output cuts, a 41% surge in raw material quotations, and rising cross-border inspection costs, it launched a customized procurement project from China in 2025.
Mandatory customized specifications set by the client: Silymarin seeds must be sourced from standardized GAP plantations in the Hetao Irrigation District of Inner Mongolia; scattered roadside harvested seeds and moldy defective seeds are prohibited. Core indicators: Silymarin ≥80%, with silybin accounting for ≥30%. Two customized grades are specified:
1. High-purity medicinal extraction powder: Refined via resin treatment with zero ethanol solvent residue, for OTC liver-protecting capsules;
2. Cold-water instant modified powder: No excipients such as maltodextrin or starch added, exclusively for liver-protecting oral liquids, with no precipitation after 90 days of storage at 4°C.
Annual fixed customized procurement volume: 20.2 tons.
The client independently contacted three domestic plant extract manufacturers for sampling and customization at the initial stage. A total of 9 batches of samples were sent to Germany’s authoritative laboratory PhytoLab for testing, and pilot production trials were carried out in its EU GMP preparation workshop. Six major customization obstacles emerged successively: mixed inferior seed raw materials, unstable ratios of active components, degradation of silybin caused by high-temperature extraction, excessive solvent residues, poor powder properties unsuitable for differentiated formulation processing, and incomplete EU compliance documents. The new product launch was delayed by 87 days, with equivalent losses of EUR 23,500 incurred from testing fees, scrapped auxiliary materials, and production line debugging losses.
Most domestic manufacturers mass-produce generic national standard-grade silymarin raw materials using traditional ethanol extraction and spray-drying processes, lacking capabilities including targeted procurement of GAP raw materials, low-temperature staged refining, and special powder modification. They cannot meet the client’s non-standard customized parameters for differentiated grades. Upon recommendation by the European Medicinal Plant Raw Materials Association, the client fully entrusted HiSiaddi with overall foreign trade coordination to implement full-process customization covering designated seed source control, graded low-temperature extraction and refining, dual-grade powder modification, and complete EU compliance supporting documentation.
Suppliers purchased scattered silymarin seeds from across the country, randomly blending high-quality Hetao seeds, low-priced aged Northeast seeds, and moldy fallen seeds as feedstock. The silymarin base content of seeds from different producing areas varies drastically: high-quality Hetao seeds feature a base silymarin content of 22%–25%, while inferior aged seeds only reach 11%–14%. There is no control over blending ratios, resulting in finished silymarin content fluctuating widely between 73% and 82%, with silybin proportion mostly below 26% — failing to steadily meet the mandatory standard of ≥30% silybin. HPLC chromatograms show excessive impurity peaks, which fail to meet German Pharmacopoeia feedstock requirements.
Silybin is a thermosensitive active component. Traditional manufacturers adopt prolonged ethanol reflux extraction above 78°C, leading to over 32% degradation loss of silybin under high temperatures. Even with high-quality seed feedstock, finished silybin content still fails to reach the standard, and unbalanced component ratios directly reduce the bioavailability of end pharmaceuticals.
Conventional processes lack closed negative-pressure solvent recovery systems, leaving ethanol residues in finished products generally above 6,500 ppm — far exceeding Germany’s internal medicinal raw material limit of ≤3,000 ppm. When used in medicinal capsules, excess ethanol causes gelatin shells to soften and leak.
After extraction, manufacturers uniformly produce coarse powder via standard spray drying without supporting production lines for cyclodextrin inclusion modification and graded crushing. The coarse powder hardly dissolves in cold water and forms brown flocculent precipitates during low-temperature storage of oral liquids; uneven powder particle sizes cause bridging and agglomeration during automatic capsule filling, with filling weight errors exceeding 7%.
Crude extracts retain large amounts of plant oils and crude fiber impurities. When compounded with vitamin and lecithin excipients for capsule production, the powder turns light yellow to dark brown after 50 days of ambient storage, failing to meet the EU’s 24-month shelf-life standard for finished products.
German drug authorities require supporting documents including Inner Mongolia GAP field planting records, plant protection logs, SGS full EC396 226-item pesticide residue reports, English COAs, and REACH registration documents. Original manufacturers only provided domestic self-inspection reports with complete gaps in traceability and compliance documentation, risking detention and return of goods at customs upon arrival.
HiSiaddi assembled a cross-functional team consisting of plant extraction engineers, EU compliance specialists, and third-party testing coordinators. It screened two mid-to-high-end plant extract manufacturers with designated Inner Mongolia seed procurement qualifications and closed low-temperature refining production lines, implementing the workflow of locking designated GAP seed sources → low-temperature staged extraction → multi-stage resin graded refining → differentiated powder modification by formulation type → EU compliance documentation filing. Verification was conducted in three phases: 100g lab samples, 80kg pilot trials, and mass production with repeated adjustments.
HiSiaddi conducted on-site inspections in Bayannur’s Hetao production area of Inner Mongolia and signed annual exclusive seed harvesting agreements with 3 certified large-scale GAP planting cooperatives. Mechanical centralized harvesting is scheduled after full ripening each autumn, with shriveled, moldy, and fallen defective seeds manually eliminated. Each batch of seeds is accompanied by field pesticide usage logs, origin planting registration certificates, and batch quality inspection reports. Raw materials are tested for native silymarin base content upon entry; entire batches with a base below 22% are rejected, eliminating mixed inferior seeds and stabilizing the baseline of active ingredients from the source.
The high-temperature full reflux process was discarded and replaced with customized low-temperature percolation + gradient ethanol extraction + negative-pressure low-temperature concentration + macroporous resin staged refining. Extraction is conducted at a constant low temperature of 42°C with staged gradient ethanol extraction under fully closed and light-shielded conditions, limiting silybin degradation to within 6%. Multi-stage resin treatment removes plant oils and crude fiber impurities stepwise, delivering finished silymarin at a stable range of 79.8%–80.5% and silybin at 30.1%–31.2%, precisely matching the client’s two internal control indicators. A three-stage closed rectification system controls ethanol residues strictly below 2,800 ppm, under Germany’s medicinal raw material limit.
1. Refined medicinal powder for OTC capsules: Low-temperature vacuum drying followed by nitrogen-sealed air-flow crushing optimizes powder repose angle to 33°±2°. The powder boasts excellent fluidity without additional anti-caking agents, enabling clog-free automatic capsule filling with precise filling weights.
2. Water-soluble modified powder for oral liquids: Low-temperature β-cyclodextrin inclusion modification without added fillers such as starch or maltodextrin. The powder dissolves instantly in cold water and remains crystal clear with zero precipitation after 90 days of storage at 4°C, perfectly matching oral liquid formulations.
Multi-stage resin refining deeply removes pro-oxidant impurities including plant oils and heavy metal ions. Meanwhile, HiSiaddi coordinated with the German R&D department to adjust feeding procedures: silymarin extract, vitamins, and lecithin excipients are pre-mixed separately and added in batches to reduce catalytic oxidation triggered by metal ions. Accelerated stability testing shows no discoloration after 90 days of sample storage.
Documents compiled and filed in accordance with German drug regulatory formats include Inner Mongolia GAP planting archives, seed origin certificates, SGS full EC396 226-item pesticide residue test reports, English COAs with HPLC chromatograms, REACH pre-registration documents, English MSDS, and LFGB packaging material certificates. Pre-submission to assist the client with pre-filing for German importers.
After 5 rounds of cross-border sample delivery, full testing by Germany’s PhytoLab, and pilot production acceptance in the client’s EU GMP workshop, both customized raw material grades passed pre-inspection for German customs entry. The first batch of 5.5 tons of products was vacuum-packed with nitrogen-filled aluminum foil bags and shipped from Shanghai Port to Hamburg, passing random German customs inspection for one-time clearance and warehousing.
After raw material launch, the capsule production line operated stably for 33 consecutive days with filling weight errors controlled within ±1.9%, and the scrap rate dropped from the original 29% to 1.1%. All batches of oral liquid showed no precipitation under low-temperature storage. The new product whose launch had been delayed by 87 days was successfully listed in Germany’s OTC auxiliary dietary catalogue and rolled out across national chain pharmacies.
The client immediately signed a long-term framework procurement order for an annual volume of 20.2 tons: 12.4 tons of medicinal capsule powder and 7.8 tons of oral liquid water-soluble powder, with monthly production scheduling split into 12 batches throughout the year. A follow-up customized low-irritation silymarin extract for premium liver-protecting gummies was added, with all process debugging, sampling, and compliance coordination fully managed by HiSiaddi. Compared with raw materials imported from Hungary, comprehensive customized procurement costs decreased by 31.2%, and sea freight lead time was shortened from 82 days to 22 days.
In the following year, Hepapharma expanded its market coverage to Austria and Belgium relying on stable raw material supply and added customized medicinal-grade silymarin for pet liver care. Backed by this German pharmaceutical brand reference case, cooperating manufacturers optimized standardized production lines for customized silymarin and subsequently secured long-term orders from three equivalent pharmaceutical enterprises in the Netherlands and Switzerland, breaking free from the low-price homogenized competition of domestic crude powder products.
Most domestic plant extract manufacturers focus on mass production of low-cost generic silymarin crude powder, with scattered raw material procurement and fixed outdated production processes. They lack capabilities for refined graded refining and powder modification, and hold insufficient systematic knowledge of EU Pharmacopoeia, LFGB, REACH and other regulations. Mid-to-high-end European pharmaceutical enterprises specialize in preparation R&D and are well-versed in local drug regulatory standards, yet lack familiarity with the chaotic domestic raw material supply chain and process gaps in China. Independent direct sourcing easily leads to customized project failures, delayed new product launches, and substantial economic losses.
Leveraging origin resources, extraction technology, and cross-border compliance resources, HiSiaddi connects the full industrial chain covering GAP designated raw material control, customized low-temperature refining, differentiated powder modification by formulation, and cross-border compliance support. It bridges technical and information gaps between overseas customized demand and domestic production capacity, supporting high-end medicinal-grade Chinese silymarin extract to steadily enter the European pharmaceutical raw material supply chain.
If you require further customized services, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
